Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
85 hedge funds and large institutions have $239M invested in Concert Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 25 increasing their positions, 28 reducing their positions, and 20 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
80% more capital invested
Capital invested by funds: $133M → $239M (+$106M)
12% more call options, than puts
Call options by funds: $879K | Put options by funds: $788K
4.67% more ownership
Funds ownership: 58.14% → 62.81% (+4.7%)
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
4% less funds holding
Funds holding: 89 → 85 (-4)
11% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$26.4M |
| 2 |
BlackRock
New York
|
+$13.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$5.17M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.63M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.54M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$4.89M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$3.35M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.85M |
| 5 |
NC
Nexthera Capital
New York
|
-$1.73M |
CNCE Hedge Fund Activity: Q1 2017 in Review
85 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2017, worth a combined $239M — up 80% from $133M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CNCE positions and 20 closed out — a net gain of 1 holder — while 25 added to existing stakes and 28 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $26.4M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $5.54M sold.
- 85 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2017, down from 89 in Q4 2016.
- Funds reported $239M of Concert Pharmaceuticals, Inc. stock for Q1 2017, up 80% quarter-over-quarter.
- 21 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2017 and 20 closed out, a net change of +1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2017 was Great Point Partners, an estimated $26.4M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2017 was Cormorant Asset Management, an estimated $5.54M sold.
Based on aggregated 13F filings for Q1 2017.